Muscle loss 6 months after surgery predicts poor survival of patients with non-metastatic colorectal cancer

被引:5
|
作者
Zhang, Liang [1 ,2 ]
Guan, Junjie [3 ]
Ding, Chao [2 ]
Feng, Min [2 ]
Gong, Longbo [1 ]
Guan, Wenxian [2 ]
机构
[1] Xuzhou Cent Hosp, Dept Gastrointestinal Surg, Xuzhou, Peoples R China
[2] Nanjing Med Univ, Dept Gen Surg, Drum Tower Clin Med Coll, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Univ Tradit Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Gen Surg, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China
来源
FRONTIERS IN NUTRITION | 2022年 / 9卷
关键词
colorectal cancer; sarcopenia; skeletal muscle loss; visceral adipose tissue; survival; BODY-COMPOSITION; SKELETAL-MUSCLE; SURGICAL OUTCOMES; OBESITY PARADOX; CACHEXIA; IMPACT;
D O I
10.3389/fnut.2022.1047029
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
BackgroundMuscle loss is a common characteristic of cancer-related malnutrition and a predictor of poorer prognosis in oncological patients. This study evaluated the association between altered body composition 6 months after surgery and the prognosis in patients with non-metastatic colorectal cancer. Materials and methodsA total of 314 patients who underwent elective curative surgery were enrolled in the study. The third lumbar CT images on preoperative and 6-months postoperative were collected to calculate the skeletal muscle index (SMI), visceral adiposity index (VATI), and subcutaneous adiposity index (SATI). Sarcopenia was defined by the cut-off values reported in the literature, and risk factors affecting overall survival (OS) and disease-free survival (DFS) in CRC were analyzed using Cox regression models. ResultsEighty-two of 314 patients (26.1%) with CRC were diagnosed with sarcopenia before surgery, the preoperative sarcopenia was not significantly associated with the prognosis of CRC patients. There were significant differences in frequency of complications between patient groups according to sarcopenia (41.5 vs. 21.4%, p = 0.004). The Postoperative LOS (11.21 +/- 3.04 vs. 8.92 +/- 2.84, p < 0.001) was longer in the sarcopenia group than in the non-sarcopenia group, and 30-d readmission (24.4 vs. 6.0%, p < 0.001) was higher in the sarcopenia group compared to the non-sarcopenia group. In multivariate analysis, 6-months SMI loss > 10% after surgery was independently associated with poorer OS [hazard ratio (HR) = 3.74; 95% confidence interval (CI) 1.96 to 7.12; P < 0.001] and DFS (HR = 3.33; 95% CI, 1.71 to 6.47; P < 0.001). SMI changes were moderately correlated with changes in body mass index (BMI) (R = 0.47, P < 0.001). Conclusion6-months muscle loss after surgery may affect overall and disease-free survival and was an independent predictor of prognosis in patients with CRC.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Severe muscle loss during radical chemoradiotherapy for non-metastatic nasopharyngeal carcinoma predicts poor survival
    Huang, Xiao
    Ma, Jie
    Li, Ling
    Zhu, Xiao-dong
    CANCER MEDICINE, 2019, 8 (15): : 6604 - 6613
  • [2] Association between postoperative muscle wasting and survival in older patients undergoing surgery for non-metastatic colorectal cancer
    Argillander, Tanja E.
    Spek, Danielle
    Van der Zaag-Loonen, Hester J.
    van Raamt, A. Fleur
    van Duijvendijk, Peter
    van Munster, Barbara C.
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (07) : 1052 - 1058
  • [3] Postoperative Loss of Skeletal Muscle Mass Predicts Poor Survival After Gastric Cancer Surgery
    Tan, Shanjun
    Zhuang, Qiulin
    Zhang, Zhige
    Li, Shuhao
    Xu, Jiahao
    Wang, Junjie
    Zhang, Yanni
    Xi, Qiulei
    Meng, Qingyang
    Jiang, Yi
    Wu, Guohao
    FRONTIERS IN NUTRITION, 2022, 9
  • [4] Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer
    Blauwhoff-Buskermolen, Susanne
    Versteeg, Kathelijn S.
    de van der Schueren, Marian A. E.
    den Braver, Nicole R.
    Berkhof, Johannes
    Langius, Jacqueline A. E.
    Verheul, Henk M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (12) : 1339 - +
  • [5] Response to "Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer"
    Daly, Louise E.
    Ryan, Aoife M.
    Power, Derek G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3816 - +
  • [6] Development and validation of nomograms for predicting survival in patients with non-metastatic colorectal cancer
    Jiang, Huihong
    Tang, Erjiang
    Xu, Dan
    Chen, Ying
    Zhang, Yong
    Tang, Min
    Xiao, Yihua
    Zhang, Zhiyong
    Deng, Xiaxing
    Li, Huaguang
    Lin, Moubin
    ONCOTARGET, 2017, 8 (18) : 29857 - 29864
  • [7] Compliance with the ERAS Protocol and 3-Year Survival After Laparoscopic Surgery for Non-metastatic Colorectal Cancer
    Pisarska, Magdalena
    Torbicz, Grzegorz
    Gajewska, Natalia
    Rubinkiewicz, Mateusz
    Wierdak, Mateusz
    Major, Piotr
    Budzynski, Andrzej
    Ljungqvist, Olle
    Pedziwiatr, Michal
    WORLD JOURNAL OF SURGERY, 2019, 43 (10) : 2552 - 2560
  • [8] Compliance with the ERAS Protocol and 3-Year Survival After Laparoscopic Surgery for Non-metastatic Colorectal Cancer
    Magdalena Pisarska
    Grzegorz Torbicz
    Natalia Gajewska
    Mateusz Rubinkiewicz
    Mateusz Wierdak
    Piotr Major
    Andrzej Budzyński
    Olle Ljungqvist
    Michał Pędziwiatr
    World Journal of Surgery, 2019, 43 : 2552 - 2560
  • [9] Response to "Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer" Reply
    Blauwhoff-Buskermolen, Susanne
    de van der Schueren, Marian A. E.
    Langius, Jacqueline A. E.
    Verheul, Henk M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3817 - +
  • [10] Pan-immune-inflammatory values predict survival in patients after radical surgery for non-metastatic colorectal cancer: A retrospective study
    Li, Kejin
    Zeng, Xiangyue
    Zhang, Ziyi
    Wang, Kuan
    Pan, Yipeng
    Wu, Zhimin
    Chen, Yi
    Zhao, Zeliang
    ONCOLOGY LETTERS, 2025, 29 (04)